Can a daily pill match the weight loss of injectable GLP-1 drugs?
In this phase 2 trial, a once-daily oral GLP-1 pill called elecoglipron helped adults with obesity or overweight lose about 10.5% of their body weight by week 26, compared with 0.6% for those taking a placebo.
GLP-1 drugs have changed how doctors treat obesity. They copy a natural gut hormone that tells your brain you are full and slows down how fast your stomach empties. The catch is that most of these drugs are shots you inject under your skin. Elecoglipron is different. It is a small-molecule pill you swallow once a day, taken without food or fluid restriction, which could make this kind of treatment far easier for people who dislike needles.
What the data show
The trial enrolled 310 adults who had obesity, defined as a BMI of 30 kg/m2 or higher, or were overweight with a BMI of at least 27 kg/m2 plus at least one weight-related condition. None of them had type 2 diabetes. Their mean age was 48.4 years, mean body weight was 106.9 kg, and mean BMI was 38.2 kg/m2. Total treatment duration was 36 weeks, and the main weight measurements came at week 26. The researchers compared five elecoglipron regimens against placebo: 5 mg, 15 mg, 50 mg, and two different titration schedules for 75 mg.
The results followed a clear, dose-dependent pattern. At week 26, estimated mean weight change ranged from 2.6% at the 5 mg dose to 10.5% at 75 mg with weekly titration steps, compared with 0.6% on placebo.
The proportion of people who hit a meaningful threshold shifted just as much. Between 40.4% and 88.8% of participants on elecoglipron reached at least 5% weight loss by week 26, depending on the dose, versus 15.6% on placebo.
Dr. Kumar’s Take
The delivery is what interests me. An effective oral GLP-1 pill could open this treatment to a much wider group of people. Plenty of my patients want help with weight but balk at the idea of weekly injections, and a daily tablet removes that barrier. The dose-response pattern here is clean, which is exactly what I want to see from a phase 2 study: it tells the developers which doses are worth carrying into phase 3.
That said, I want to keep expectations grounded. This is a phase 2 dose-ranging trial, which is an early and fairly small step. Only 75% of participants completed the assigned treatment, and that gap between study completion and treatment completion is worth watching in larger studies. Larger and longer phase 3 trials are needed to confirm the weight loss holds up and to track side effects over time. Promising is not the same as proven.
How the studies were done
This was a double-blind, randomised, placebo-controlled clinical trial, which is the gold standard for testing a new drug. Randomised means people were assigned to their group by chance, and placebo-controlled means one group took a matching inactive pill for comparison. Double-blind means participants, treating physicians, and the sponsor were all masked to who received what. This design helps make sure the weight loss came from the drug and not from other changes in diet or lifestyle.
It was also a multicentre trial, running at medical research centres and hospitals in Australia, Canada, Germany, Japan, Taiwan, the UK, and the USA. Multicentre means it ran at several locations, which makes the findings more reliable than a single-site study. Phase 2 is the stage where researchers test whether a drug works and find the right dose before moving to the larger phase 3 trials that decide if it reaches the market. The trial was funded by AstraZeneca, the company developing the drug, and several authors are employees and stockholders of the company.
Safety, limits, and caveats
The side effects looked like what doctors already expect from GLP-1 drugs. The most common complaints were nausea, constipation, diarrhoea, headache, and vomiting. Adverse events were reported by 84% to 98% of participants across the elecoglipron doses, compared with 84% in the placebo group, so the gap between drug and placebo on overall adverse events was narrower than those raw numbers first suggest.
The bigger limits are about scale and time. With 310 participants and a 36-week treatment period, this trial was not built to catch rare side effects or to show what happens after a year or two. It also excluded people with type 2 diabetes, so I cannot assume the same results apply to them yet. These are the questions that larger phase 3 trials will need to answer.
Practical Takeaways
- An oral GLP-1 pill is still experimental, so do not expect to find elecoglipron at the pharmacy yet, as it must clear larger phase 3 trials first.
- If you are interested in GLP-1 treatment now, talk to your doctor about the approved injectable options and whether you are a good candidate.
- Nausea, constipation, diarrhoea, headache, and vomiting were the most common adverse events in this trial, so ask your doctor what to watch for.
- Dose matters. In this trial the lowest dose produced 2.6% weight loss and the highest produced 10.5%, so the regimen your doctor chooses shapes the result.
- Remember that medication works best alongside healthy eating and regular movement, not as a replacement for them.
Related Studies and Research
- Can a daily pill keep weight off after weight-loss shots?
- Time-restricted eating improves sleep, mood, and quality of life in overweight adults
- Creatine for type 2 diabetes: a placebo-controlled trial
- Single-dose psilocybin shows rapid, sustained antidepressant effects
FAQs
How is an oral GLP-1 pill different from injectable GLP-1 drugs?
The main difference is how you take it. The familiar GLP-1 medicines are injected under the skin. Elecoglipron is a small-molecule drug you swallow as a tablet once a day, and it does not require food or fluid restrictions around dosing. Small-molecule means it is built to survive your digestive system and still work, which is hard to do with the larger protein-based injectable drugs. The goal is to deliver similar benefits without the needle.
How much weight did people actually lose in this trial?
At week 26, the highest dose, 75 mg with weekly titration, produced an estimated mean reduction of 10.5% of starting body weight. People taking the placebo lost 0.6%. The effect was dose-dependent, with the lowest 5 mg dose producing 2.6%. Looked at another way, 40.4% to 88.8% of people on elecoglipron reached at least 5% weight loss depending on dose, versus 15.6% on placebo.
When could this pill be available?
It is too early to say. This was a phase 2 dose-ranging trial, which tests whether a drug works and helps pick the right dose. Before any medicine reaches the public, it usually must pass larger phase 3 trials that involve far more people over longer periods. Those studies confirm both the benefits and the safety. The authors say these results support phase 3 investigation, so while the findings are promising, approval would likely still be years away.
Bottom Line
An oral GLP-1 pill that produced 10.5% weight loss at its highest dose by week 26 is a meaningful step forward, because it could bring the benefits of GLP-1 therapy to people who cannot or will not use injections. In this phase 2 trial, elecoglipron produced dose-dependent weight loss against 0.6% on placebo, with the familiar GLP-1 side effects of nausea and other gut symptoms. The findings are early and need confirmation in larger trials, but a once-daily weight-loss pill in this range would be a real change in how obesity is treated.
